ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO467

APOL1 Genotypes and Vascular and Endothelial Function in the Multi-Ethnic Study of Atherosclerosis (MESA)

Session Information

Category: Hypertension and CVD

  • 1401 Hypertension and CVD: Epidemiology, Risk Factors, and Prevention


  • Chen, Teresa K., Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Katz, Ronit, University of Washington, Seattle, Washington, United States
  • Estrella, Michelle M., University of California, San Francisco and San Francisco VA Medical Center, San Francisco, California, United States
  • Post, Wendy S., Johns Hopkins University, Baltimore, Maryland, United States
  • Kramer, Holly J., Loyola University Medical Center, Maywood, Illinois, United States
  • Rotter, Jerome I., LABioMed at Harbor-UCLA Medical Center, Torrance, California, United States
  • Tayo, Bamidele O., Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States
  • Mychaleckyj, Josyf, University of Virginia, Charlottesville, Virginia, United States
  • Wassel, Christina, Premier, Inc, Charlotte, North Carolina, United States
  • Peralta, Carmen A., University of California San Francisco/SFVAMC, San Francisco, California, United States

The APOL1 high-risk genotypes, present in 13% of U.S. blacks, are associated with an increased risk for hypertension-attributed kidney disease. Biopsy studies show differences in kidney vasculature by APOL1 status, but less is known about the variants' associations with systemic vascular and endothelial function.


Using a recessive genetic model, we examined the cross-sectional associations of APOL1 risk genotypes (high=2 risk alleles; low=0-1 risk allele) with subclinical measures of vascular and endothelial function in MESA. Outcomes included measures of vascular (small and large arterial elasticity [SAE, LAE] by HDI PulseWave CR-2000 and ascending aortic distensibility [AAD] by magnetic resonance imaging) and endothelial (by brachial artery Doppler flow-mediated dilation [FMD]) function. We constructed linear regression models, adjusting for age, sex, and genetic global ancestry.


We included African-American MESA participants with available APOL1 genotyping and measurements of SAE (n=1586), LAE (n=1586), AAD (n=985), and FMD (n= 777) at Exam 1 (2000-2002). Mean age was 62 years, 54% were female, 59% had hypertension, mean systolic blood pressure was 131 ± 22 mmHg, and mean eGFRCysC was 90 ± 20 ml/min/1.73 m2. Mean (SD) SAE, LAE, AAD, and FMD were 4.2 (2.5) ml/mmHg*100, 13.5 (5.8) ml/mmHg*100, 1.7 (1.3) 1/mmHg*1000, and 0.2 (0.1) mm, respectively. In linear regression models, the APOL1 high-risk genotypes were not associated with SAE, LAE, AAD, or FMD, though there was a trend of lower AAD among APOL1 high- vs. low-risk individuals (Table).


Among African Americans in MESA, the APOL1 high-risk genotypes were not associated with subclinical measures of vascular or endothelial function. Further studies are needed to clarify the potential role of APOL1 in vascular changes.


  • NIDDK Support